Merck Sharp + Dohme Corp.

Lexicon Pharmaceuticals, Inc.

Bristol-myers Squibb Compnay

Qinghong Fu

Haifeng Tang

Alexander Pasternak

David John Augeri

Jinlong Jiang

Jessica Frie

Marianne Carlsen

Kenneth Gordon Carson

Fa-Xiang Ding

Zhi-Cai Shi

Xin Gu

Shuzhi Dong

Takao Suzuki

Alexander Heim-Riether

Jerry Andrew Taylor

Theodore C Jessop

Brian Cato

James E Tarver

Reynalda K DeJesus

Paul E Finke

Barbara A Pio

Emma R Parmee

Dooseop Kim

Songnian Lin

Shawn P Walsh

Eldon Scott Priestley

Xiaojun Zhang

Michael Voronkov

Xibin Liao

Aurash Shahripour

Jeremy M Richter

Zhiqiang Guo

Oz Scott Halpern

Reynalda Keh Dejesus

Samuel Kaye Reznik

Jason Patrick Healy

Michael Mertzman

Zhifa Pu

Roman Kats-Kagan

Christian P Stevenson

Xiaolian Xu

James Tarver, Jr

Doan Hackley

Philip E Keyes

Min Shen

Ronald Dale Ferguson

Reynalda K Dejesus

Disclosed are compounds of Formula (I) to (IV): or a stereoisomer, tautomer, pharmaceutically acceptable salt, solvate or prodrug thereof. Also disclosed are methods of using such compounds as PAR4 inhibitors, and pharmaceutical compositions comprising such compounds. These compounds are useful in inhibiting or preventing platelet aggregation, and are useful for the treatment of a thromboembolic disorder or the primary prophylaxis of a thromboembolic disorder. 

Bicyclic heteroaryl substituted compounds

The present invention provides compounds of Formula I (I) and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. 

Inhibitors of the renal outer medullary potassium channel

The present invention provides compounds of Formula I and the pharmaceutically acceptable salts thereof, which are inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention.

Novel spirocyclic compounds of formula I: and pharmaceutically acceptable salts thereof are disclosed as inhibitors of the ROMK (Kir1.1) channel. The compounds may be used as diuretic and/or natriuretic agents and for the therapy and prophylaxis of medical conditions including cardiovascular diseases such as hypertension, heart failure and chronic kidney disease and conditions associated with excessive salt and water retention. Pharmaceutical compositions and methods of treatment are also included. 

This invention relates to compounds having structural Formula I: and pharmaceutically acceptable salts thereof which are inhibitors of the Renal Outer Medullary Potassium (ROMK) channel (Kir1.1). The compounds of Formula I are useful as diuretics and natriuretics and therefore are useful for the therapy and prophylaxis of disorders resulting from excessive salt and water retention, including cardiovascular diseases such as hypertension and chronic and acute heart failure.

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use

Aryl pyridines, compositions comprising them, and methods of their use for the treatment, prevention and management of a variety of diseases and disorders are disclosed.

Aryl pyridines and methods of their use

4-Amino-1H-pyrimidin-2-one-based compounds, compositions comprising them, and methods of their use for the treatment, prevention and management of various diseases and disorders are disclosed. Particular compounds are of formula I: 

4-amino-1H-pyrimidin-2-one based compounds, compositions comprising them and methods of their use

O-linked pyrimidin-4-amine-based compounds, pharmaceutical compositions comprising them, and methods of their use are described. Particular compounds of the invention are of formula I: 

O-linked pyrimidin-4-amine-based compounds, compositions comprising them, and methods of their use to treat cancer

Growing community of inventors

Plainsboro, NJ, United States of America

Qinghong Fu